INS and Ovarian Hyperandrogenism: From a medicinal standpoint, engineered hepatocyte-derived EVs harbouring anti-miR-122 antagomirs have the ability to modulate hepatic lipid metabolism (via SREBP1c suppression), reduce systemic insulin levels, and indirectly alleviate ovarian hyperandrogenism.